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Abstract: This work describes the development, optimisation and validation of an 23 
analytical method for the rapid determination of 17 priority pharmaceutical compounds 24 
and endocrine disrupting chemicals (EDCs). Rather than studying compounds from the 25 
same therapeutic class, the analyses aimed to determine target compounds with the 26 
highest risk potential with regard to Scotland, providing a tool for further monitoring in 27 
different water matrices. Prioritisation was based on a systematic environmental risk 28 
assessment approach, using consumption data; wastewater treatment removal efficiency; 29 
environmental occurrence; toxicological effects; and pre-existing regulatory indicators. 30 
This process highlighted 17 compounds across various therapeutic classes, which were 31 
then quantified, at environmentally relevant concentrations, by a single analytical 32 
methodology. Analytical determination was achieved using a single-step solid phase 33 
extraction (SPE) procedure followed by high-performance liquid chromatography with 34 
tandem mass spectrometry (HPLC-MS/MS). The fully optimised method performed well 35 
for the majority of target compounds, with recoveries >71% for 15 of 17 analytes. The 36 
limits of quantification for most target analytes (14 of 17) ranged from 0.07 ng·L-1 to 1.88 37 
ng·L-1 in river waters. The utility of this method was then demonstrated using real water 38 
samples associated with a rural hospital/setting. Eight compounds were targeted and 39 
detected, with the highest levels found for the analgesic, paracetamol (at up to 105910 40 
ng·L-1 in the hospital discharge). This method offers a robust tool to monitor high priority 41 
pharmaceutical and EDC levels in various aqueous sample matrices. 42 
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Introduction 52 
The discovery and use of pharmaceuticals is one of society’s greatest advances, leading 53 
to increased human lifespan and promoting improved health (Johansson, 1998). An 54 
unintended consequence of the widespread use of human pharmaceuticals has however 55 
been their inadvertent and now ubiquitous introduction into the aquatic environment. This 56 
commonly occurs as a result of the excretion (in urine/faeces) of unmetabolised parent 57 
compounds and the improper disposal of unused or expired medicinal products – both of 58 
which pass into sewage networks (where these are present) and then remain in treated 59 
wastewater discharges (Cahill et al., 2004; Charuaud et al., 2019; Fekadu et al., 2019; 60 
Kallenborn et al., 2018). Numerous studies have now demonstrated the incomplete 61 
removal of pharmaceuticals by sewage treatment systems, with as much as 80% of the 62 
total load of any particular pharmaceutical entering the treatment network ultimately 63 
being released into the receiving aquatic environment (Botero-Coy et al., 2018; Östman 64 
et al., 2018; Ruan et al., 201; Yuan et al., 2014). 65 
The potential effects of pharmaceutical pollution may include the promotion of multi-66 
drug resistant bacterial strains and/or deleterious acute or chronic ecotoxicological 67 
impacts on non-target organisms (Brodin et al., 2013; Hernando-Amado et al., 2019; 68 
Kumar et al., 2019). For example, fluoxetine has been shown to cause reproductive delay 69 
in leopard frogs (Foster et al., 2010; Fursdon et al., 2019; Hellström et al., 2016), while 70 
ciprofloxacin can cause genotoxic effects in plankton and algae (Carusso et al., 2018) 71 
(Dionísio et al., 2020). Further, certain pharmaceuticals are also endocrine disrupting 72 
chemicals (EDCs), and have been shown to exert significant reproductive effects even at 73 
trace environmental levels. For example, 17α-ethinylestradiol (a synthetic hormone 74 
commonly used in birth control pills) has been extensively studied in fish and shown to 75 
cause delays in embryonic development (Almeida et al., 2020; Huff et al., 2018), 76 
vitellogenin induction (Zhang et al., 2019; Zhou et al., 2019), intersex development 77 
(Jackson et al., 2019; Ujhegyi and Bókony, 2020) and thus reduced reproductive success 78 
(Colman et al., 2009; Roy et al., 2018). 79 
The ongoing discharge of pharmaceuticals and EDCs into the wider environment 80 
potentially poses a risk to human health and as such there remains a need to evaluate their 81 
presence, fate and behaviour in various environmental compartments. This requires the 82 
development of robust, sensitive and accurate analytical methods for the simultaneous 83 
extraction, detection and quantification of these chemicals at low, environmentally 84 
relevant levels. The most common analytical approach to determine pharmaceuticals and 85 
EDC levels in aqueous samples first involves a pre-concentration step (i.e., using solid 86 
phase extraction; SPE), and then the use of liquid chromatography with mass 87 
spectrometric detection (LC-MS) (Buchberger, 2011;.Hong et al., 2019; Peng et al., 2019). 88 
However, many methods focus on compounds that are simply most commonly found (i.e., 89 
in water), or, that belong to specific drug classes, i.e., antibiotics (Gurke et al., 2015a, 90 
2015b; Rossmann et al., 2014; Scheurer et al., 2009). As such, there remains a need to 91 
develop techniques specifically focussed on those substances thought to pose the greatest 92 
risk potential within the aquatic environment. Such methods can be informed by existing 93 
prioritisation systems such as those which have led to the creation of “Watch Lists” within 94 
the EU Water Framework Directive (WFD, EU) and the UK’s Chemical Investigation 95 
Program (CIP, UK) (European commission, 2015; UKWIR, 2015). Such regulatory 96 
indicators act to highlight those compounds thought to be of most concern and/or 97 
requiring more detailed research.  98 
In this study, we describe the development of an SPE protocol combined with subsequent 99 
HPLC-MS/MS (high performance liquid chromatography with tandem mass 100 
spectrometry) analysis for the routine determination of selected pharmaceuticals and 101 
EDCs (first prioritised based on their high environmental risk potential). The work 102 
presented involves: (1) prioritisation of compounds across a range of therapeutic classes 103 
– all with significant potential to pose risks to the aquatic environment; (2) development 104 
of a rapid and sensitive method to measure these compounds at environmentally relevant 105 
concentrations (ng·L-1); (3) an evaluation of possible matrix effects using different water 106 
types; and (4) application of the methodology to real samples collected from a range of 107 
sites as part of a hospital discharge focused monitoring study.  108 
1. Methodologies and chemicals 109 
1.1 Chemicals and reagents 110 
All prioritised compound standards were of the highest purity available (>98%) and 111 
supplied by Sigma-Aldrich (UK). Isotopically labelled internal standards were purchased 112 
from Qmx. Both individual compound stock standards and isotopically labelled internal 113 
standards (ILIS) were prepared in methanol, except for ciprofloxacin, which was 114 
dissolved in methanol containing 1 µM NaOH to enhance solubility. Mixed compound 115 
standards and calibration standards were prepared using appropriate dilutions of 116 
individual stock solutions, in 50:50 v/v methanol:Milli-Q® water. All solutions were 117 
stored in amber glass vials at −20℃ in the dark. 118 
HPLC-grade acetonitrile, ethyl acetate, acetone and methanol were provided by VWR 119 
Chemicals (Poole, England). Formic acid, acetic acid, ammonium acetate and ammonium 120 
hydroxide were all analytical grade and supplied by Sigma–Aldrich. Oasis HLB 6cc (200 121 
mg) and Oasis HLB Prime 6cc (200 mg) SPE cartridges were obtained from Waters 122 
Corporation (Milford, MA, USA).  123 
1.2 Instrumentation  124 
The quantification of target analytes was performed using a HPLC-MS/MS system, 125 
consisting of an Agilent 1100 HPLC with a CTC PAL auto-sampler coupled to a 126 
Micromass Quattro Ultima Platinum mass spectrometer (Manchester, UK) equipped with 127 
an electrospray ionisation source (ESI). Ions were acquired in multiple reaction 128 
monitoring (MRM) mode. Precursor ions for each compound were determined by direct 129 
infusion of individual compound standards whilst in full-scan mode (at m/z 50-1000). 130 
During infusion the optimum cone voltage (CV) to achieve maximum signal response for 131 
each ion was selected. Product ion scanning was then performed to obtain product ions, 132 
and collision energy (CE) was optimised for each individual analyte. The highest intensity 133 
characteristic precursor to product ion MRM transition was used for quantification 134 
(quantifier), while a second was used for confirmation (qualifier). To sustain an adequate 135 
signal response for every compound, analytes were measured within optimised time 136 
windows. Data acquisition and analysis were carried out using MassLynx 4.1 software 137 
(Micromass, Manchester, UK).  138 
1.3 Sample preparation 139 
SPE was employed for sample enrichment and clean-up, and several stationary phases 140 
were tested under a range of elution conditions to optimise compound recovery (see Fig. 141 
S1 for schematic of the process). All SPE experiments were conducted in triplicate, using 142 
20 mL of Milli-Q water spiked to a starting concentration of 10 µg·L-1 for each analyte 143 
(ultimately 500 µg·L-1 in final extract/following the SPE process, assuming 100% 144 
recovery). For the final protocol, SPE cartridges were preconditioned with methanol (6 145 
mL) and then Milli-Q water (6 mL), both at a flow rate of 1 mL·min-1. 20 mL spiked 146 
water samples were passed through the cartridges at a flow rate of 1 mL·min-1 and then 147 
cartridges were rinsed with Milli-Q water once (1 mL). Cartridges were then dried under 148 
vacuum for >30 min to remove excess water. Then, the analytes were eluted with two 149 
consecutive 6 mL elution’s using methanol (MEOH), or, acetone (ACE) and ethyl acetate 150 
(EAC) at 50:50 v/v (depending on desired recoveries for certain compounds), at 1 151 
mL·min-1. The eluates were then evaporated under a gentle stream of high purity nitrogen 152 
at 40℃ until they were almost dry, then reconstituted with 0.4 mL of 50:50 v/v 153 
MEOH:Milli-Q. Absolute recoveries were determined compared to quality-control (QC) 154 
standards of 500 µg·L-1. 155 
1.4 Method quantification  156 
Compound selectivity was verified by measuring two MRM transitions per analyte. 157 
Calibration linearity was studied by analysing standards in triplicate at nine 158 
concentrations in the range from 2 to 500 µg·L-1. Satisfactory linearity using weighed 159 
(1/x) least squares regression was assumed when the correlation coefficient (R2) was > 160 
0.99. Method accuracy and precision (expressed as recovery and repeatability, using 161 
relative standard deviation) were studied with recovery experiments (using Milli-Q water 162 
spiked with analytes). Instrumental limits of detection (LOD) for each compound were 163 
determined as the minimum detectable amount of analyte giving a signal-to-noise (S/N) 164 
ratio of 3 (using the quantification transition).  165 
For the investigation regarding matrix effects, a known amount of analyte (10 µg·L-1) and 166 
ILIS (1 µg·L-1) was added to tap water and river water (filtered and unfiltered). Taking 167 
into account an enrichment factor of 50 (whereby 20 mL of water sample was 168 
reconstituted into 0.4 mL for analysis following SPE), quality-control (QC) standards of 169 
500 µg·L-1 (for the analytes) and 50 µg·L-1 (for the ILIS) were then used for quantification.  170 
1.5 Application to real samples  171 
A range of water samples were collected from sites associated with/in the vicinity of a 172 
rural UK hospital (in Caithness, Scotland). These were (1) the local potable untreated 173 
surface water source, (2) the hospital water inflow, (3) the hospital combined wastewater 174 
effluent discharge, (4) the combined local municipal WWTP influent and (5) the 175 
combined effluent from the same municipal WWTP (for Wick town, Caithness). A sub-176 
set of 8 target compounds were monitored over 4 weeks at these sites. Water samples (2 177 
L) were collected in amber glass bottles and 1 L was filtered through 0.7 µm glass 178 
microfiber filters (47 mm, MF300, Fisher Scientific, UK). Filtrates were spiked with 0.25 179 
mL of ILIS mixed standard working solution (at 100 µg·L-1; equivalent to a 25 ng·L-1 180 
concentration in 1 L of sample). SPE cartridges were preconditioned with MEOH and 181 
Milli-Q water, then 1L water samples were passed through the cartridges at a flow rate of 182 
1 mL·min-1. The SPE extract was eluted with 2×6 mL MEOH and reconstituted with 0.5 183 
mL of 50:50 v/v MEOH:Milli-Q, leading to an enrichment factor of 2,000 and a final 184 
concentration of 100 µg·L-1 ILIS in the analysed sample. Quantification was made using 185 
external QC standards and calibration standards, with recovery assessed based on relative 186 
responses. To ensure the precision and accuracy of the data required, all targeted 187 
compounds in real water analysis have been assigned with their own ILIS standards to 188 
correct possible quantification errors. All samples were stored at 4℃ in the dark until SPE 189 
extraction, which was performed within 48 hr of sample collection.  190 
2. Results and Discussion 191 
2.1 Prioritisation of target compounds  192 
As there are > 3,000 pharmaceuticals registered for use in the European Union (EU), it is 193 
necessary to prioritise these whilst accounting for risk (Boxall et al., 2012). Many 194 
prioritisation schemes have been proposed in recent years, commonly based on 195 
consumption data, environmental occurrence and/or toxicological effects (Kötke et al., 196 
2019; Li et al., 2020; Mansour et al., 2016; Pereira et al., 2016; Roos et al., 2012). 197 
However, many field monitoring studies still focus on compounds that are most 198 
commonly found in water (López-Serna et al., 2011; Rossmann et al., 2014) – many of 199 
which may (or may not) be likely to elicit toxicological effects.  200 
Here, a systematic prioritisation approach was first used to identify compounds that may 201 
pose the greatest risk in the aquatic environment. For the evaluation of the environmental 202 
risk of pharmaceuticals and EDCs, it is difficult to estimate if adverse effects (both acute 203 
and chronic toxicity as well as other potentially more subtle biological and behavioural 204 
effects) on non-target organisms occur at environmentally relevant concentrations. In this 205 
study, a risk score was used as a primary prioritisation parameter to characterize 206 
substances that pose potential ecological risks to the aqueous environment by comparing 207 
their environmental occurrence with their known toxicologically relevant concentrations. 208 
The risk score - hazard quotient (HQ) value was calculated as the ratio between measured 209 
environmental concentration (MEC) and the predicted no effect concentration (PNEC; 210 
i.e., the environmental level at which no adverse effect on relevant non-target 211 
organisms/ecosystem function is expected) (Booth et al., 2020). When the HQ ≥ 1, a high 212 
risk of adverse effects is expected (De Souza et al., 2009; Ccanccapa et al., 2016). 213 
Although there are (as yet) no legally binding discharge limits set in the EU for 214 
pharmaceuticals and EDCs, multiple compounds have been highlighted as ‘priority 215 
substances’ for further investigation by EU and UK regulatory frameworks, i.e., through 216 
‘Watch Lists’ created as part of the EU Water Framework Directive (WFD) and the 217 
priority lists created through the UK’s Chemical Investigation Programme (CIP) 218 
(European commission, 2018; UKWIR, 2019). These result in increased monitoring and 219 
research and may ultimately lead to statutory discharge limits for certain compounds 220 
(Brack et al., 2017; Miarov et al., 2020; Nijsingh et al., 2019; Petrie et al., 2015; 221 
Voulvoulis et al., 2017). As such, these regulatory indicators have also been taken into 222 
account here. 223 
 224 
Fig.1. Decision tree of compound prioritisation 225 
Here, the first step in our prioritisation process was to consider prescription rates within 226 
Scotland. As shown in Fig.1, pharmaceuticals were first grouped by therapeutic class, 227 
and within each class, compounds prescribed >100,000 times per year (ISD Scotland, 228 
2016) were highlighted. Substances prescribed below this value were only highlighted if 229 
they had been listed as existing priorities within the EU’s WFD Watch List(s) and/or the 230 
UK’s CIP Programme. Analytes highlighted were then evaluated further by considering 231 
WWTP removal efficiency, reported environmental concentrations (in water) and 232 
toxicological risk. Combining the reviewed range of pharmaceutical and EDC monitoring 233 
data (MEC) and their PNEC values, the risk scores were calculated to characterize 234 
substances that have pose potential adverse effects to the aqueous environment at current 235 
detection levels. All preliminarily prioritised substances were then considered in terms of 236 
their physico-chemical properties – and where these had very similar molecular structures 237 
(which may then result in similar environmental fate), a single substance was selected as 238 
representative of a certain group.  239 
The prioritisation selection criteria applied here were, in summary: a) prescription 240 
statistics (ISD Scotland, 2016); b) legislative indicators, i.e., WFD ‘Watch List’ and/or 241 
UK CIP listed; c) removal efficiency in WWTP; d) environmental occurrence in water; 242 
e) biological toxic effects (informed by HQ calculated with PNEC and MEC); and f) 243 
physico-chemical properties. Table 1 shows a summary regarding the prioritised list of 244 
compounds targeted in this study (Li et al., 2019).   245 
















Log Kow pKa 
Antibiotic 
(anti-infective) 
Trimethoprim 487128 No 0-50 10-28000 500 56 0.9 7.1 
Antibiotic 
(macrolide) 
Clarithromycin 268489 EUa,b+UK4 0-24 3.5-621 250 2.5 3.2 8.9 
Antibiotic 
(Fluoroquinolone) 
Ciprofloxacin 99441 EUb+UK 45-78 6–2500 100 25 0.3-0.7 
5.9; 
8.9 
Antimicrobial Triclosan 10-1000 t/yr5 UK 45-89 3.9-434 50 8.68 4.2-4.8 7.9 
Analgesic Paracetamol 5482031 No 0-90 160-65000 1000 65 0.5-0.9 9.5 
NSAID6 Ibuprofen 915788 UK 72-90 44–990000 1650 600 4.0 4.9 
NSAID Diclofenac 595709 EUa+UK 9-60 10–510000 3310 154 4.5 4.2 
SSRI7 Fluoxetine 816346 UK 3-60 2.1-2000 110 18.2 1.2 10.1 




N/A8 UK N/A 8-2100 N/A N/A 1.26 13.9 
β-blocker Propranolol 557628 UK 34-80 108-1130 244 4.63 0.78 9.5 
Blood lipid regulator Atorvastatin 1637000 UK 40-80 10-210 86 2.44 6.36 4.46 
Anti-diabetic Metformin 1140162 UK 0-85 100-47000 13450 3.49 1.3 12.4 
Steroid hormone 
(Natural) 










298045 EUab+UK 0-85 0.36-4.3 0.35 12.3 3.67–4.15 10.4 
Steroid hormone 
(Natural) 9 
Estriol (E3) N/A No 0-90 0.11-18 60 0.3 2.55-2.81 10.4 
1. Prescription statistics for Scotland 2014-15 (ISD Scotland, 2016); 2. Predicted no-effect concentration (PNEC); 3. Hazard quotient (HQ) incorporating MEC with PNEC; 4. EU a. 
Commission Implementing Decision 2015/495 (European commission, 2015); b. 2018/840 (European commission, 2018); UK, Chemical Investigation Programme (UKWIR, 2019); 5. 
Triclosan usage in EU per year; 6. Nonsteroidal anti-inflammatory drugs (NSAIDs); 7. Selective serotonin reuptake inhibitors (SSRIs); 8. N/A, not applicable/available. 9. References 
used for the prioritisation data are listed in Table. S1 (supporting information). 
Ultimately, 17 compounds were identified as priority substances here, belonging to a wide 246 
range of compound classes (11), i.e., antibiotics, antimicrobials, analgesics, non-steroidal anti-247 
inflammatory drugs, psychoactive drugs, β-blockers, blood lipid regulators, antidiabetics, anti-248 
ulcer agents and estrogens (as well as associated metabolites). Fifteen compounds were 249 
associated with high potential risk (HQ>1) within the aqueous environment, including 250 
ibuprofen, diclofenac, paracetamol, trimethoprim, E2, ciprofloxacin, fluoxetine, EE2, 251 
carbamazepine, E1, propranolol, metformin, clarithromycin, atorvastatin and triclosan (in HQ 252 
value order from high to low). This largely aligns with key legislative indicators (given these 253 
were also one of our criteria), with the only pharmaceutical compounds in addition to CIP/WFD 254 
indicators being trimethoprim and paracetamol. These two compounds have been highlighted 255 
as their current occurrence levels outstrip its known toxicologically relevant concentrations 256 
(PNEC) as shown in Table 1, the high HQ scores of trimethoprim (56) and paracetamol (65) 257 
indicated that the adverse effects on non-target organisms may occur in the aquatic environment. 258 
Trimethoprim is the second most commonly prescribed antibiotic in Scotland, and reports show 259 
that up to 80% of this is excreted unmetabolised by the human body (De Liguoro et al., 2012; 260 
Kasprzyk-Hordern et al., 2009). It has been found to be resistant to the biological wastewater 261 
treatment (Lindberg et al. 2006), one of the most frequently occurring antibiotics found in UK 262 
wastewaters, being detected in 65% of effluent samples with a maximum concentration of 1,300 263 
ng·L-1 (Ashton, Hilton & Thomas 2004). Similarly, paracetamol is one of the most commonly 264 
prescribed drugs globally, due to its antipyretic and analgesic properties. Even though the 265 
reported removal efficiencies in WWTPs are relatively high (up to 90%), it is often found at 266 
high levels in the aquatic environment (e.g., maximum 10,000 ng·L-1 in US natural waters and 267 
at 65,000 ng·L-1 in the River Tyne, UK) (Kolpin et al., 2002; Roberts and Thomas, 2006). Such 268 
high levels of paracetamol continuously introduced into the aquatic environment have been 269 
found to cause negative ecological effects in various wild organisms (Nunes et al., 2014), the 270 
high HQ scores of these compounds in this study reinforced the necessity of further 271 
investigation of such pollutants.  272 
UK CIP (UKWIR, 2019) identified a wide range of substances that may pose a significant risk 273 
to the environment in the UK. Following the prioritisation procedure used here, fourteen 274 
compounds on CIP were prioritised for investigation. At EU level, priority substances were first 275 
introduced under the WFD Commission Implementing Decision (EU) 2015/495, which listed 276 
ten watch list substances, and required this list to be updated every two years according to 277 
Commission Implementing Decision (EU) 2008/105 (European commission, 2008). 278 
Accordingly, diclofenac was originally prioritised in the first WFD watch list (European 279 
commission, 2015) and monitored intensively. On the basis of sufficient high-quality 280 
monitoring data available for this compound, diclofenac has since been removed from the watch 281 
list in June 2018 (European commission, 2018). Meanwhile, the antibiotic ciprofloxacin has 282 
been added due to its potential to drive antimicrobial resistance in the environment. Macrolide 283 
antibiotics (clarithromycin, erythromycin and azithromycin) have been retained in the watch 284 
list, while, clarithromycin, the highest prescribed macrolide, was chosen as the representative 285 
compound, based on the fact that these substances have similar molecular structures and 286 
physico-chemical properties.  287 
As well as ‘parent’ pharmaceutical compounds, one of the 17 compounds listed here is a 288 
metabolite. While most studies tend to focus on primary pharmaceuticals, there is now 289 
increased recognition that excreted metabolites may also pose risks in the environment (Roberts 290 
and Thomas, 2006). Carbamazepine, one of the most prominent anti-epileptic drugs with annual 291 
worldwide usage of 1,014 tons and 223,601 prescription in Scotland has been targeted in this 292 
study due to the poor removal in WWTP, high detection levels and potential risks in the 293 
environment (ISD Scotland, 2016; Radjenović, Petrović & Barceló 2009). As well as ‘parent’ 294 
pharmaceutical compound, the metabolite of carbamazepine, carbamazepine-10-11-epoxide 295 
has been found to be biologically active and shows similar or higher toxicity relative to its 296 
parent compound (Calisto and Esteves, 2009; Miao and Metcalfe, 2003). Therefore, 297 
carbamazepine-10-11-epoxide has been included as a representative metabolite. Moreover, 298 
there are several potent natural estrogens of concern (estrone (E1), 17 β-estradiol (E2) and 299 
estriol (E3)), which are not dissimilar to the synthetic xenoestrogen - 17α-ethynyl estradiol 300 
(EE2) which has been of concern for many years (Burkhardt-Holm, 2010; Czarny et al., 2019; 301 
Qin et al., 2020; Yu et al., 2019). Three of these four EDCs (E1, E2 and EE2) have also been 302 
highlighted by both the EU’s WFD Watch List schemes and the UK’s CIP system. As estriol 303 
(E3) poses ecotoxicological effects similar to E1, E2, and EE2, this estrogen has also been 304 
targeted for investigation here. 305 
2.2 Detection method development  306 
2.2.1 HPLC separation and MS/MS optimisation  307 
To optimise compound separation and sensitivity, methanol and acetonitrile along with 308 
different buffers (ammonium acetate, ammonium hydroxide, formic acid and acetic acid at 309 
various concentrations) were tested as mobile phases. MS parameters were optimised to attain 310 
maximum sensitivity and selectivity. Of the 17 substances, 10 showed a higher response using 311 
the protonated [M+H]+ ions and positive ion (PI) mode while 7 were better using negative mode 312 
(detecting the deprotonated [M−H]− ions). For both modes, several HPLC columns and various 313 
operational parameters/gradient designs (i.e., different flow rates and slopes) were tested in 314 
order to optimise peak separation, signal response and minimise run time. Good peak shape and 315 
sensitivity were achieved in PI mode using a reverse-phase Waters XBridge BEH C18 column 316 
(2.1 mm I.D. x 100 mm, 2.5 µm) with 0.1% formic acid as the aqueous phase and acetonitrile 317 
at 45℃. For the 7 NI compounds, sufficient separation was obtained using 0.025% ammonium 318 
hydroxide (in water) and acetonitrile and a Phenomenex Kinetex EVO C18 column (3.0 mm 319 
I.D x 100 mm, 2.6 µm) at 25℃. The optimised gradient elution programs used are shown in 320 
Table S2 (Supporting Information) alongside representative chromatograms for pure standard 321 
mixtures monitored in both modes (Fig. S2). Optimised mass spectrometry parameters, 322 
precursor and product ions, retention times (RT) and instrumental LODs in both PI and NI 323 
modes are summarised in Table 2 and 3, respectively. 324 
325 
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Ibuprofen 206 205 35 161 4 2.21 Diclofenac-D4 
 
0.272 













































































1. CV - cone voltage; 2. CE - collision energy; 3. RT - retention time; 4. LOD - limit of detection. 329 
All compounds had two abundant product ions, except ibuprofen, for which only one was 330 
monitored due to poor fragmentation. Transitions identified here are in agreement with those 331 
from other studies (Löffler and Ternes, 2003; Jelić et al., 2009; Ferrer et al., 2010; Golet et al., 332 
2001). 333 
2.2.2 Optimisation of Solid Phase Extraction (SPE) procedure 334 
A number of SPE protocols (different cartridges, elution solvents, pH conditions, etc.) were 335 
evaluated for pharmaceutical and EDC recovery. The choice of SPE stationary phase can play 336 
a crucial role in enhancing recovery of analytes and SPE selection is frequently based on the 337 
physico-chemical properties of target compounds. Here, the lipophilic-hydrophilic-balanced, 338 
reverse-phase polymeric sorbent Oasis HLB cartridge was used to accommodate the wide range 339 
of physico-chemical characteristics exhibited by the prioritised pharmaceuticals and EDCs 340 
(with pKa ranging from 4.2 to 13.9, and Log Kow from 0.28-6.36). This cartridge has also been 341 
shown to be less susceptible to matrix effects than other media (Gorga et al., 2013; Van De 342 
Steene et al., 2006; Vazquez-Roig et al., 2010). Two HLB cartridges (Oasis HLB and Oasis 343 
HLB Prime) were evaluated using methanol and acetone:ethyl acetate at 50:50 v/v as solvents. 344 
To study any pH related recovery effects, different solution pH values were tested (i.e., no pH 345 
adjustment or pH = 2). The average absolute recoveries (and relative standard deviations (SD)) 346 
for each target compound are shown in Table 4. 347 
To evaluate possible quantification errors introduced by analyte loss during sample processing 348 
and fluctuations in instrument sensitivity, 1 µg·L-1 of ILIS was added as a surrogate to samples 349 
prior to extraction (ILIS = 50 µg·L-1 post-SPE, assuming 100% recovery). The ILIS compounds 350 
applied in this study were selected based on the following criteria: (i) a 2H-isotope or a 13C 351 
labelled isotope compound - which shared the same (or very similar) physico-chemical 352 
properties to the analyte; (ii) with a chromatographic retention time close to that of the analyte; 353 
(iii) and similar SPE recovery and ionisation response to the analyte. Given the large number 354 
of compounds targeted here it was unfeasible to correct each analyte with its own individual 355 
ILIS, hence, ILIS analogues were used for certain groups (i.e., E1-D2 for the four estrogens) 356 
on the basis of compound similarity, retention time and recovery. Relative recoveries 357 
(calculated using the recovery data for the ILIS compounds), and the ILIS compounds used, are 358 
presented in Table 5. 359 
Table 4. Absolute mean SPE recoveries of prioritised pharmaceuticals and EDCs using different SPE protocols 
No. 
Recoveries 
% and (±%RSD) 
Analytes detected in -ve mode Analytes detected in +ve mode No. >75% 
and 
<125% IBU DCF E3 E2 EE2 E1 TCS MET PARA CFX TMP CBZE PPL CBZ CTM FLX ATV 
1 MEOH 
HLB 
35 67 38 36 41 44 34 45 90 2 38 59 39 51 49 35 10 
1 
(±17) (±4) (±10) (±6) (±5) (±6) (±2) (±16) (±6) (±0) (±1) (±1) (±3) (±1) (±6) (±0) (±1) 
HLB Prime 
71 83 65 75 87 56 67 74 93 2 56 90 68 83 45 45 12 
6 
(±10) (±3) (±4) (±4) (±0) (±10) (±11) (±6) (±2) (±0) (±1) (±1) (±4) (±2) (±1) (±5) (±2) 
2 ACE:EAC 
HLB 
56 77 37 33 40 49 59 11 90 3 38 65 6 52 26 1 11 
2 
(±5) (±2) (±10) (±14) (±13) (±3) (±2) (±12) (±4) (±3) (±2) (±7) (±1) (±3) (±5) (±0) (±3) 
HLB Prime 
90 91 97 111 101 107 98 11 99 1 42 98 28 102 26 0 27 
10 






29 30 29 30 38 53 53 3 72 195 34 5 47 49 26 45 10 
0 
(±2) (±3) (±72) (±1) (±1) (±0) (±3) (±1) (±2) (±21) (±1) (±1) (±1) (±0) (±3) (±0) (±4) 
HLB Prime 
43 46 63 66 63 104 77 3 96 145 74 22 81 85 27 84 11 
6 






57 36 27 29 37 49 62 2 81 36 42 20 40 54 9 32 6 
1 
(±1) (±1) (±3) (±4) (±5) (±0) (±10) (±0) (±1) (±11) (±8) (±1) (±8) (±6) (±1) (±2)  (±1) 
HLB Prime 
58 63 73 77 75 121 91 1 88 144 56 25 91 94 14 46 14 
7 
(±6) (±0) (±1) (±4) (±3) (±19) (±8) (±1) (±6) (±2) (±0) (±1) (±4) (±11) (±1) (±1) (±3) 
 
Table 5. Mean SPE recoveries of prioritised pharmaceuticals and EDCs calculated using the ILIS recovery data to correct responses 
No 
Recoveries 
% and (±%RSD) 
Analytes detected in -ve mode Analytes detected in +ve mode No. >75% 
and 
<125% 
IBU DCF E3 E2 EE2 E1 TCS MET PARA CFX TMP CBZE PPL CBZ CTM FLX ATV 
Applied ILIS DCF-D4 E1-D2 TCS-D3 TMP-D9 CBZ-D10 RTM FLX-D5 
1 MEOH 
HLB 
48 77 66 60 56 88 101 49 64 1 51 94 60 85 129 45 39 
5 
(±21) (±3) (±13) (±5) (±4) (±2) (±6) (±5) (±1) (±0) (±6) (±10) (±2) (±4) (±4) (±1) (±3) 
HLB Prime 
64 92 112 103 96 97 92 102 210 4 117 95 63 88 126 85 113 
12 
(±6) (±3) (±8) (±6) (±5) (±3) (±4) (±26) (±19) (±1) (±3) (±1) (±0) (±1) (±4) (±1) (±5) 
2 ACE:EAC 
HLB 
69 77 77 91 104 91 97 3 85 3 45 126 3 89 127 83 80 
10 
(±5) (±1) (±4) (±10) (±7) (±10) (±1) (±0) (±18) (±2) (±9) (±7) (±0) (±0) (±11) (±24) (±17) 
HLB Prime 
80 94 96 99 93 96 99 31 227 2 113 99 29 90 135 82 123 
12 






56 77 46 57 83 71 93 1 40 62 95 3 77 80 104 95 9 
8 
(±3) (±0) (±2) (±2) (±11) (±4) (±2) (±0) (±2) (±4) (±2) (±1) (±8) (±3) (±4) (±1) (±0) 
HLB Prime 
147 101 66 83 92 103 110 4 126 221 134 33 116 120 133 95 67 
8 






79 80 64 74 100 67 103 1 63 61 92 21 79 86 111 88 10 
9 
(±6) (±1) (±7) (±9) (±3) (±17) (±4) (±0) (±4) (±9) (±7) (±0) (±1) (±2) (±0) (±2) (±1) 
HLB Prime 
161 101 98 117 116 99 107 2 98 186 110 28 109 102 130 95 114 
12 
(±13) (±1) (±25) (±46) (±36) (±14) (±2) (±1) (±5) (±11) (±1) (±4) (±2) (±1) (±8) (±2) (±56) 
Where particular low/high recoveries have been observed, these are shaded grey for ease of noting (<35% / >135% - dark grey; <75%/ >125% - light grey). Metformin MET; Paracetamol PARA; 
Trimethoprim TMP; Ciprofloxacin CFX; Carbamazepine-10-11-epoxide CBZ; Propranolol PPL; Carbamazepine CBZ; Clarithromycin CTM; Fluoxetine FLX; Atorvastatin ATV; Ibuprofen IBU; 
Diclofenac DCF; Estriol E3; 17β-Estradiol E2; 17α-ethynylestradiol EE2; Estrone E1; Triclosan TCS. Trimethoprim-D9 TMP-D9; Carbamazepine-D10 CBZ-D10; Roxythromycin RTM; Fluoxetine-D5 
FLX-D5; Diclofenac-D4 DCF-D4; Estrone-D2 E1-D2; Triclosan-D3 TCS-D3. Methanol MEOH; acetone ACE; ethyl acetate EAC.
 
Recoveries obtained varied markedly between compounds and SPE conditions used (as 360 
may be expected given the physico-chemical diversity of the prioritised compounds). It 361 
is evident that data corrected for ILIS recovery (Table 5) provided better results for most 362 
target compounds (as compared to absolute recovery data; Table 4). This was most 363 
evident for the analytes clarithromycin, fluoxetine, trimethoprim and the estrogens. This 364 
indicated that analyte losses occurred throughout the analytical procedure and that ILIS 365 
correction helped ensure better quantification (compensating for any losses).  366 
In terms of SPE, higher recovery values were achieved using the Oasis HLB Prime 367 
cartridges under the tested conditions. The Oasis HLB Prime provided satisfactory 368 
recoveries (>75% and <125%) for more analytes (Table 4 and 5), which may be attributed 369 
to the strong hydrophobic interaction between analytes and retention sorbent of HLB 370 
prime cartridges (Beltran et al., 2010). For the extremely polar compound metformin, 371 
which was previously reported as not recoverable using an SPE procedure, satisfactory 372 
recoveries (102% ± 26%) were observed in condition 1 (Cahill et al., 2004). 373 
A dependency on SPE pH was observed for certain substances. For instance, the ILIS 374 
corrected recovery for propranolol and trimethoprim was enhanced at pH 2, while for 375 
carbamazepine-epoxide and metformin it was reduced. Notably, ciprofloxacin was 376 
overestimated when using acidified conditions, which may be attributed to pH-induced 377 
molecular conformation changes. Ciprofloxacin has a zwitterionic nature and exists in 378 
cation, zwitterion, and/or anion species under different pH conditions (see Fig. S3). We 379 
postulate that the acidification of the SPE process to pH 2 charged the cationic amine 380 
moiety positively, resulting in an increased number of ions entering the MS. The 381 
dependency of substances with a zwitterionic nature on pH has also been reported by 382 
other authors (Rossmann et al., 2014).  383 
Regarding the optimal SPE conditions, 12 of 17 compounds were recovered at >75% and 384 
<125% in tested conditions 1, 2 and 4 based on the ILIS correction (Table 5). Using 385 
absolute recoveries (Table 4), condition 2 was found to be most effective (>75% recovery 386 
for 10 compounds with HLB Prime). The ILIS corrected values (Table 5) were generally 387 
in agreement with the absolute recoveries (Table 4), with the enhancement of recoveries 388 
(Table 5) in conditions 1 and 4 suggesting the ILIS correction appropriately ensured 389 
successful quantification by compensating for losses of compounds.  390 
 
The ‘optimal’ SPE condition that provided the best recovery for each compound varied 391 
due to the variety of physico-chemical properties represented in the priority list. For most 392 
target compounds, condition 2 was found the most effective based on the high values of 393 
both absolute and ILIS corrected recoveries, therefore was selected for further study. 394 
Meanwhile, low recovery was noted for certain substances (metformin, ciprofloxacin and 395 
propranolol <35%) in this condition. To reach a compromise, that gives an acceptable 396 
recovery for most compounds with the least loss, condition 1, retaining 16 out of 17 397 
compounds, with the exception of ciprofloxacin, was also selected for further 398 
investigation.  399 
Although quantitation with ILIS assured sufficient recoveries, under certain 400 
circumstances, the use of ILIS can be a complicated approach for analytes from a diverse 401 
range of chemical classes (Gracia-Lor et al., 2011). Quantitation with ILIS needs to be 402 
well characterised when it does not ensure an adequate correction. For instance, 403 
undesirable enhancement of ILIS recovery was observed for paracetamol while 404 
satisfactory absolute values (72-99%) were obtained under tested conditions. Similar 405 
inadequate ILIS recovery was found for ibuprofen. This was attributed to the mass loss 406 
of its ILIS analogue not coinciding with the analyte under the same conditions so that the 407 
ILIS calculation exaggerated the process efficiency, making the ILIS correction 408 
unnecessary (Marín et al., 2009; Renew and Huang, 2004). Therefore, the absolute 409 
recoveries of paracetamol and ibuprofen have been adopted for evaluation.  410 
2.3 Matrix effect study 411 
The influence of environmental matrix on accurate quantitative LC-MS/MS analysis has 412 
been widely discussed (Frigerio et al., 2019; Fu et al., 2018; Huang et al., 2020). Non-413 
target components present in samples can have a significant impact on analyte recovery 414 
and ionisation which may deplete or enhance MS signal intensity and thus affect accurate 415 
quantification (Irlam et al., 2019; Meerpoel et al., 2018; Tran et al., 2020). The assessment 416 
of matrix effect has been conducted in a number of approaches during the development 417 
of quantitative analytical method, the most commonly used one may refer to the “absolute” 418 
matrix effect, comparing the signal response of a standard present in an extract containing 419 
co-eluting components to the response of a standard in a “not contaminated” neat solvent 420 
(Matuszewski et al., 2003). Although the presence of this absolute matrix effect (which 421 
is often obtained by a comparison of the response of analyte spiked after extraction to the 422 
 
response in the neat solution) is of some concern, the more important parameter in the 423 
evaluation of an analytical method is the demonstration of the absence of a “relative” 424 
matrix effect in different sources of environmental water matrices. To validate the overall 425 
performance of the analytical method in this study, the effects of water matrices were 426 
evaluated by comparing recoveries of analytes in different water matrices (spiked before 427 
extraction). The suppression or enhancement of recoveries in Table 6 demonstrated the 428 
overall effects of matrices (undetected coeluting components reacting with primary ions 429 
formed in the HPLC−MS/MS interface) and recoveries (competition with matrix 430 
components, which can largely be compensated by isotope-labeled internal standards) 431 
from different water sources. All values presented were corrected using ILIS, except for 432 
paracetamol and ibuprofen, where absolute recoveries are given (due to inadequate ILIS 433 
correction as discussed above). 434 
With a number of exceptions, fairly limited effects of matrix were observed for many of 435 
these pharmaceuticals and EDCs, which is consistent with previous findings (Cha et al., 436 
2006; Tong et al., 2009; Tuc Dinh et al., 2011). Some effects were noted for 6 compounds, 437 
with >50% recovery suppression for two (atorvastatin and ibuprofen), ~20-40% 438 
suppression for three (metformin, paracetamol and clarithromycin) and <20% 439 
enhancement for trimethoprim. This was likely due to ion suppression in the MS ESI 440 
source due to matrix components (Gómez et al., 2006; Kasprzyk-Hordern et al., 2008). 441 
The lack of ILIS correction for paracetamol and ibuprofen likely made these effects more 442 
obvious and meant effective correction could not be achieved. For atorvastatin, its high 443 
Log Kow (6.36) suggests the compound would tend to bind with organic matter present in 444 
water – and the SPE process presumably failed to overcome this. For several analytes 445 
(e.g., E3, paracetamol, trimethoprim, clarithromycin), a filtered river water matrix 446 
resulted in lower recovery versus unfiltered, indicating no filtration is beneficial to remain 447 
pharmaceutical compounds when recovering them from environmental water matrices. 448 
This may be attributed to the pharmaceutical analytes sorbed onto suspended particular 449 
matter present in the river samples, which was then removed during membrane filtration, 450 
causing the concentrations of freely dissolved analytes to be lower for further detection. 451 
The co-extracting components in river water matrix may also mask the analyte peaks by 452 
raising the chromatogram baseline, leading to underestimated integrated peak areas. 453 
Meanwhile, the co-extracting matrix may reduce ionisation efficiency of the analytes by 454 
taking up some of the limited number of excess charged sites on the surfaces of 455 
 
electrosprayed droplets (Gómez et al., 2006).This is consistent with other studies and may 456 
suggest that analysing samples without filtration may sometimes be more appropriate 457 
(depending on the analytes concerned and aims of the study) (Berset and Ochsenbein, 458 
2012; Tran et al., 2013). For filtered river samples, methanol elution provided better 459 
recoveries for most target compounds in this study. In terms of limits of quantification 460 
(LOQs) calculated when processing 1 L of water - these were in the range of 0.07 ng·L-1 461 
to 9.07 ng·L-1 (as shown in Table 6). For 14 out of 17 compounds (excluding ibuprofen, 462 
ciprofloxacin and E3), method LOQs were 0.07 ng·L-1 to 1.88 ng·L-1 , which is somewhat 463 
lower than those previously reported in other studies (Choi et al., 2007; Ding et al., 2009; 464 
Tuc Dinh et al., 2011).  465 
 
Table 6. Recoveries of prioritised pharmaceuticals and EDCs in different water matrices (using ILIS correction, except for paracetamol and ibuprofen) 
Recoveries 
% and (±%RSD) 
Analytes detected in -ve mode Analytes detected in +ve mode No. >75% 
and 
<125% 
IBU DCF E3 E2 EE2 E1 TCS MET PARA CFX TMP CBZE PPL CBZ CTM FLX ATV 
Applied ILIS  DCF-D4 E1-D2 TCS-D3 TMP-D9  TMP-D9 CBZ-D10 RTM FLX-D5 
MEOH 
Milli-Q 
71 92 112 103 96 97 92 102 93 4 117 95 63 88 126 85 113 13 
(±10) (±3) (±8) (±6) (±5) (±3) (±4) (±26) (±2) (±1) (±3) (±1) (±0) (±1) (±4) (±1) (±5) 
Tap  
Water 
32 100 129 116 115 95 96 47 51 26 137 112 60 101 105 100 43 9 
(±3) (±1) (±9) (±5) (±21) (±1) (±0) (±11) (±5) (±10) (±2) (±3) (±4) (±2) (±9) (±3) (±0) 
River water 
Unfiltered 
5 99 112 98 102 96 109 44 62 6 131 110 65 97 108 93 14 10 
(±4) (±2) (±14) (±10) (±15) (±3) (±1) (±2) (±3) (±5) (±8) (±1) (±6) (±3) (±3) (±4) (±5) 
River water  
Filtered 
14 100 81 103 104 96 107 60 55 10 124 111 73 97 89 95 55 11 




90 94 96 99 93 96 99 31 99 2 113 99 29 90 135 82 123 13 
(±6) (±1) (±6) (±4) (±3) (±3) (±3) (±7) (±2) (±1) (±2) (±1) (±7) (±0) (±16) (±5) (±7) 
Tap  
Water 
40 97 96 99 92 90 105 2 67 1 130 101 21 96 103 94 6 10 
(±2) (±1) (±4) (±2) (±12) (±4) (±4) (±1) (±5) (±0) (±7) (±2) (±5) (±2) (±5) (±5) (±3) 
River water 
Unfiltered 
13 97 96 98 93 98 106 3 57 1 121 107 33 88 107 97 4 11 
(±4) (±1)  (±23) (±6) (±4) (±3) (±2) (±0) (±9) (±2) (±8) (±3) (±9) (±0) (±5) (±2) (±2) 
River water  
Filtered 
13 105 81 97 98 95 100 3 56 1 119 112 39 92 104 103 57 11 
(±1) (±2) (±6) (±1) (±5) (±1) (±4) (±1) (±6) (±0) (±32) (±8) (±11) (±4) (±2) (±6) (±0) 
 
Method LOQ  
(ng·L-1) 
9.07 0.78 4.48 1.31 1.88 0.66 1.61 0.27 0.69 4.46 0.08 0.09 0.39 0.11 0.07 0.10 0.70 
 
Where clearest reductions in recovery are evident (i.e., matrix effects most likely), these have been shaded grey for ease of noting (>50% dark grey; 20-40% light grey; reduction owing to suspended particulate 
matter- medium grey). .Metformin MET; Paracetamol PARA; Trimethoprim TMP; Ciprofloxacin CFX; Carbamazepine-10-11-epoxide CBZ; Propranolol PPL; Carbamazepine CBZ; Clarithromycin CTM; 
Fluoxetine FLX; Atorvastatin ATV; Ibuprofen IBU; Diclofenac DCF; Estriol E3; 17β-Estradiol E2; 17α-ethynylestradiol EE2; Estrone E1; Triclosan TCS. Trimethoprim-D9 TMP-D9; Carbamazepine-D10 
CBZ-D10; Roxythromycin RTM; Fluoxetine-D5 FLX-D5; Diclofenac-D4 DCF-D4; Estrone-D2 E1-D2; Triclosan-D3 TCS-D3. Methanol MEOH; acetone ACE; ethyl acetate EAC.
 
2.4 Analysis of real water samples 466 
To validate the applicability of this method, it was applied to identify and quantify 8 467 
priority pharmaceuticals and EDCs in various real water samples (to fit in the target of 468 
the hospital monitoring project – possible detected analytes based on local description 469 
data). Given the matrix effects observed in testing, an additional ILIS (paracetamol-D4) 470 
was applied (relevant recovery data was provided in Supporting information Table S3). 471 
Monitoring results are presented in Table 7. 472 
Table 7. Summary of the field monitoring results obtained for 8 target compounds (ng·L-1) in 473 
real water samples. Samples collected from a combined rural hospital discharge (Wick General, 474 
Scotland), and, the influent and effluent from Wick municipal WWTP  475 
Compound 












































































EE2 0 <LOD 0 <LOD 0 <LOD 
Beyond those sites shown in Table 7, no target pharmaceuticals were detected (>LOQ) 476 
in the surface source water or the treated hospital drinking water supply tested. Likewise, 477 
EE2 was never found (< LOQ = 1.88 ng·L-1), the method LOD standard of which has 478 
been updated to 0.035 ng·L-1 based on the Commission Implementing Decision 479 
(European Commission, 2018), suggesting the challenge and necessity of improving the 480 
analytical methodology to monitor such compounds at lower concentrations. In the 481 
hospital discharge, all the targeted pharmaceuticals were detected except EE2, with 482 
paracetamol and carbamazepine detected in every sample. The highest concentrations 483 
were recorded for paracetamol, with a maximum of 105,910 ng·L-1, followed by 484 
trimethoprim (9,111 ng·L-1) and clarithromycin (7,940 ng·L-1). Regarding the WWTP 485 
wastewater influent tested, the highest levels were noted for paracetamol (105,780 ng·L-486 
1) and ibuprofen (6,018 ng·L-1). The increased mean detection level of paracetamol 487 
(33267 ng·L-1 to 67483 ng·L-1) and ibuprofen (139 ng·L-1 to 471 ng·L-1) between the 488 
 
hospital discharge and wastewater influent indicated the possible presence of other 489 
inputting sources of such pharmaceuticals besides the hospital discharge. Lower levels of 490 
trimethoprim (818 ng·L-1 to 621 ng·L-1) and clarithromycin (1271 ng·L-1 to 246 ng·L-1)  491 
in WWTP influent versus the hospital discharge may be attributed to the degradation 492 
and/or dilution in the aquatic environment between those two sites (Gracia-Lor et al., 493 
2011). Higher levels of carbamazepine and ibuprofen may reflect greater (human) intakes 494 
in the community versus the hospital. In terms of the final WWTP effluent, all the 495 
previously detected pharmaceuticals remained detectable – albeit at reduced levels in 496 
some cases. Five of the pharmaceuticals monitored were at lower mean levels in discharge 497 
versus influent – but, two (carbamazepine, clarithromycin) were more elevated in 498 
discharge water. These results reinforce the need to apply multiclass pharmaceutical 499 
monitoring methods in order to gain a better understanding of the fate/behaviour of these 500 
compounds at the catchment scale. Likewise, they highlight the ongoing need to create 501 
WWTP processes that can efficiently eliminate these bioactive pollutants of concern. 502 
Compared to levels reported in other European countries for these target compounds 503 
(Gros et al., 2010; Gros et al., 2007; López-Serna et al., 2011), the surface water data 504 
collected here demonstrated how relatively ‘pristine’ source water can be in the Scottish 505 
Highlands (in a remote inland lake, currently entirely ‘free’ of these contaminants). 506 
However, the WWTP concentrations seen here (both influent and effluent) were highly 507 
comparable with data from Germany, Belgium and the US (Cahill et al., 2004; Gurke et 508 
al., 2015a; Rossmann et al., 2014; Vergeynst et al., 2015). This clearly highlights the 509 
impact that pharmaceutical consumption is and can have – even in remote and otherwise 510 
pristine hydrological systems.  511 
3. Conclusion 512 
A sensitive analytical methodology for the simultaneous determination of up to 17 513 
priority pharmaceuticals and EDCs was developed and validated using an optimised SPE 514 
protocol and HPLC-ESI-MS/MS detection. A risk-based approach was applied to identify 515 
compounds that may pose the greatest environmental concern. The diversity of analytes 516 
selected meant that some compromises were needed when applying this analysis (i.e., 517 
accepting reduced recovery for certain compounds). The optimal SPE protocol used Oasis 518 
HLB Prime cartridges with no pH adjustment and elution with methanol. The use of ILIS 519 
improved the reliability of the entire process and helped evaluation of matrix effects. 520 
 
Application of the method to ‘real’ environmental samples from a rural catchment in 521 
Scotland, illustrated the occurrence of pharmaceuticals in various wastewater matrices. 522 
The highest concentrations found were for paracetamol, with a mean level of 67,483 ng·L-523 
1 in municipal WWTP influent. The successful application of this method to real water 524 
matrices validated its applicability within routine monitoring studies regarding these 525 
priority pharmaceutical and EDC contaminants.  526 
Appendix A. Supplementary material 527 
Supplementary data associated with this article is present in the Supporting 528 
Information. 529 
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